ArticleDiscover oncology2025
Association of FANCD2, TFPI, and CD33 genes with prognosis of lung adenocarcinoma: a bioinformatics study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is characterized by high mortality and a complex pathogenesis. Despite significant advancements in targeted therapies and immunotherapies, patient prognosis remains poor, and there is a notable absence of effective biomarkers for early diagnosis and treatment. This study employs bioinformatics methods to identify key genes with diagnostic and therapeutic potential in LUAD and constructs a predictive model based on these genes.
methodsGenetic expression data and clinical information from LUAD patients and healthy controls were obtained from the GWAS and TCGA databases. Differentially expressed genes (DEGs) and disease-related genes were identified through Mendelian randomization (MR) analysis. GO functional enrichment and KEGG pathway analyses were performed, followed by Cox regression and LASSO regression to identify potential diagnostic and therapeutic target genes. Kaplan-Meier survival curves and a Line chart were generated to predict 1-, 3-, and 5-year survival rates.
resultsMR analysis identified 16 genes related to LUAD development, including WFDC3, FANCD2, OTX1, and others. Cox and LASSO regression pinpointed three significant genes: CD33, FANCD2, and TFPI. Kaplan-Meier curves showed higher survival rates for low-risk FANCD2 and TFPI groups, while the high-risk CD33 group had elevated survival. The calibration curve in the validation set confirmed the predictive accuracy of the model.
conclusionThis study presents a prediction model based on CD33, FANCD2, and TFPI, which could aid in individualized treatment decisions and provide a basis for further LUAD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.